Drug regulators in the US have given emergency use approval for Eli Lilly and Co's investigational monoclonal antibody therapy for the treatment of mild-to-moderate Covid-19 in adult and pediatric patients.

The treatment called, bamlanivimab, is authorised for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40kg, and who are at high risk for progressing to severe Covid-19 and/or hospitalisation, the US Food and Drug Administration (FDA) said on Monday.